Targeting mTOR and metabolism in cancer: lessons and innovations
Cancer cells support their growth and proliferation by reprogramming their metabolism in
order to gain access to nutrients. Despite the heterogeneity in genetic mutations that lead to …
order to gain access to nutrients. Despite the heterogeneity in genetic mutations that lead to …
Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications
C Pisano, M Tucci, RF Di Stefano, F Turco… - Critical reviews in …, 2021 - Elsevier
In last years several improvements have been made in the management of prostate cancer
(PCa). Androgen receptor (AR) is considered the main driver in PCa growth and progression …
(PCa). Androgen receptor (AR) is considered the main driver in PCa growth and progression …
mTOR inhibitors in castration-resistant prostate cancer: a systematic review
CM Statz, SE Patterson, SM Mockus - Targeted oncology, 2017 - Springer
Background The progression of prostate cancer to castration-resistant prostate cancer
(CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of …
(CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of …
[HTML][HTML] Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1
Resistance to docetaxel is a key problem in current prostate cancer management.
Sphingosine kinase 1 (SK1) and phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of …
Sphingosine kinase 1 (SK1) and phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of …
Targeting androgen-independent pathways: new chances for patients with prostate cancer?
C Cattrini, E Zanardi, G Vallome, A Cavo… - Critical Reviews in …, 2017 - Elsevier
Androgen deprivation therapy (ADT) is the mainstay treatment for advanced prostate cancer
(PC). Most patients eventually progress to a condition known as castration-resistant prostate …
(PC). Most patients eventually progress to a condition known as castration-resistant prostate …
Signaling pathways that control apoptosis in prostate cancer
Simple Summary Therapies that inhibit androgen receptor signaling induce cell death by
apoptosis in prostate epithelium and involution of non-malignant prostate gland, but are not …
apoptosis in prostate epithelium and involution of non-malignant prostate gland, but are not …
The EEF1A2 gene expression as risk predictor in localized prostate cancer
TS Worst, F Waldbillig, A Abdelhadi, CA Weis… - BMC urology, 2017 - Springer
Background Besides clinical stage and Gleason score, risk-stratification of prostate cancer in
the pretherapeutic setting mainly relies on the serum PSA level. Yet, this is associated with …
the pretherapeutic setting mainly relies on the serum PSA level. Yet, this is associated with …
[HTML][HTML] A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant …
K Fizazi, A Ulys, L Sengeløv, M Moe, S Ladoire… - Annals of …, 2017 - Elsevier
Background This phase II study was conducted to assess clinical efficacy of tasquinimod
maintenance therapy in patients with metastatic castrate-resistant prostate cancer not …
maintenance therapy in patients with metastatic castrate-resistant prostate cancer not …
Immunogenomic profiling and classification of prostate cancer based on HIF-1 signaling pathway
J Song, W Chen, G Zhu, W Wang, F Sun… - Frontiers in Oncology, 2020 - frontiersin.org
The HIF-1 signaling pathway plays an important role in the pathogenesis of cancer. Many
studies have explored the progression of prostate cancer (PCa) under hypoxic conditions …
studies have explored the progression of prostate cancer (PCa) under hypoxic conditions …
Safety and efficacy of docetaxel, bevacizumab, and everolimus for castration-resistant prostate cancer (CRPC)
ME Gross, TB Dorff, DI Quinn, PM Diaz… - Clinical genitourinary …, 2018 - Elsevier
Background Previous data suggests that co-targeting mammalian target of rapamycin and
angiogenic pathways may potentiate effects of cytotoxic chemotherapy. We studied …
angiogenic pathways may potentiate effects of cytotoxic chemotherapy. We studied …